Receive complimentary news updates
Just register for the Pharmaceuticals sector myFT Digest — delivered straight to your email.
Pharmaceutical firm Eli Lilly has secured US regulatory authorization to market an anti-obesity medication in oral tablet form, setting the stage for a competition with rival Novo Nordisk within the segment for ingestible weight management treatments.
The clearance for Lilly’s medication, named Foundayo, had been largely anticipated by investors for announcement this month. Nevertheless, the pharmaceutical company’s stock rose by 5 percent subsequent to its declaration of the US Food and Drug Administration’s endorsement. Lilly, headquartered in Indianapolis, stated that medical practitioners are now authorized to issue prescriptions for the tablet without delay, with deliveries to patients commencing on April 6.
Globally, Lilly holds the top position in the sales of medications for weight management and diabetes, having amassed approximately 1.5 million prescriptions in the United States up to mid-March for its injectable therapies Zepbound, Mounjaro, and Trulicity, based on Iqvia’s statistics.
However, Novo Nordisk has advanced its position against Lilly with its anti-obesity tablet, Wegovy, which was introduced in the United States at the start of January. According to analysts and those involved in the sector, Novo’s medication has achieved unprecedented sales expansion for a novel pharmaceutical product.
Prescriptions for Novo’s diabetes and weight management treatments amounted to 957,000 in the US by mid-March, as indicated by Iqvia data. Novo’s shares, traded on US exchanges, remained stable during midday commerce.
The expenses associated with anti-obesity and weight management therapies have been decreasing. To vie for a larger segment of the market and address President Donald Trump’s call for more affordable medications, Lilly and Novo have already reduced the costs of their weight-loss pharmaceuticals. Increased competition is likely to exert fresh strain on them as additional rivals join the market in the years ahead. For instance, Pfizer purchased Metsera, an emerging company focused on obesity, last year, and this entity is anticipated to introduce an injectable weight-loss treatment in 2028.
Evan Seigerman, an analyst at BMO Capital Markets, stated in a report that the “endorsement of the tablet represents a significant favorable achievement in the progression of Lilly’s obesity [and] metabolic division.” “Having secured this authorization, Lilly intends to contend head-on with Novo’s oral Wegovy medication.”
Lilly’s novel tablet distinguishes itself from Novo’s because it can be consumed alongside meals. Novo’s medication, conversely, is prescribed for ingestion half an hour prior to dining. Financial stakeholders will be keenly observing to ascertain if consumers favor one alternative more than the other, as Siegerman noted.
Lilly announced the tablet would be priced at $149 monthly for its minimum dosage, and individuals possessing insurance coverage might obtain it for as low as $25 per month. Furthermore, the medication will be accessible via specific Medicare programs at $50 each month, effective July 1. Medicare constitutes the American health insurance initiative designed for elderly individuals.